We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $80.18 · 11 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Did LivaNova's (LIVN) New Cardiopulmonary Chief from Philips Just Redefine Its Leadership Bench? - simplywall.st
Did LivaNova's (LIVN) New Cardiopulmonary Chief from Philips Just Redefine Its Leadership Bench? simplywall.st
Insider Sell Alert: Francesco Bianchi Sells Shares of LivaNova P - GuruFocus
Insider Sell Alert: Francesco Bianchi Sells Shares of LivaNova P GuruFocus
Assessing LivaNova (LIVN) Valuation After Strong 1 Year Shareholder Returns - simplywall.st
Assessing LivaNova (LIVN) Valuation After Strong 1 Year Shareholder Returns simplywall.st
LivaNova names Stefano Folli as president, CP - Medical Buyer
LivaNova names Stefano Folli as president, CP Medical Buyer
LivaNova appoints Stefano Folli to lead its cardiopulmonary business unit - MSN
LivaNova appoints Stefano Folli to lead its cardiopulmonary business unit MSN
LivaNova Hires Philips Exec Stefano Folli as President of Cardiopulmonary - Medical Product Outsourcing
LivaNova Hires Philips Exec Stefano Folli as President of Cardiopulmonary Medical Product Outsourcing
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $1.09 | — | — | $380.57M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-6.01 | — | — | $316.86M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.13 | — | — | $931.61M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.47 | — | — | $613.49M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 08. | Barclays | — | Maintain | Equal-Weight → Equal-Weight | — | Barclays: Equal-Weight |
| 2026. 05. 07. | Mizuho | — | Maintain | Outperform → Outperform | — | Mizuho: Outperform |
| 2026. 05. 07. | Baird | — | Maintain | Outperform → Outperform | — | Baird: Outperform |
| 2026. 02. 28. | Barclays | — | Maintain | Equal-Weight → Equal-Weight | — | Barclays: Equal-Weight |
| 2026. 02. 26. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 01. 10. | Barclays | — | Maintain | Equal-Weight → Equal-Weight | — | Barclays: Equal-Weight |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 381,083 | $23.45B | 0.04% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 114,714 | $7.06B | 0.01% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 47,727 | $3.03B | 0.00% | — | New position |